Monoclonal Antibody Treatment of Breakthrough COVID-19 in Fully Vaccinated Individuals with High-Risk Comorbidities

被引：38

作者：

Bierle, Dennis M. ^{[1
]}

Ganesh, Ravindra ^{[1
]}

Tulledge-Scheitel, Sidna ^{[1
]}

Hanson, Sara N. ^{[2
]}

Arndt, Lori L. ^{[3
]}

Wilker, Caroline G. ^{[4
]}

Razonable, Raymund R. ^{[1
]}

机构：

[1] Mayo Clin, Rochester, MN 55905 USA

[2] Mayo Clin Hlth Syst, Mankato, MN USA

[3] Mayo Clin Hlth Syst, Eau Claire, WI USA

[4] Mayo Clin Hlth Syst Franciscan Healthcare, La Crosse, WI USA

来源：

JOURNAL OF INFECTIOUS DISEASES | 2022年 / 225卷 / 04期

关键词：

breakthrough COVID-19; casirivimab-imdevimab; hospitalization; SARS-CoV-2; vaccination;

D O I：

10.1093/infdis/jiab570

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

Background. Breakthrough coronavirus disease 2019 (COVID-19) may occur in fully vaccinated persons. Methods. We assessed the clinical outcomes of breakthrough COVID-19 in fully vaccinated individuals. Results. In this cohort of 1395 persons (mean age, 54.3 years; 60% female; median body mass index, 30.7) who developed breakthrough COVID-19, there were 107 (7.7%) who required hospitalization by day 28. Hospitalization was significantly associated with the number of medical comorbidities. Antispike monoclonal antibody treatment was significantly associated with a lower risk of hospitalization (odds ratio, 0.227; 95% confidence interval, 0.128-0.403; P<.001). The number needed to treat (NNT) to prevent 1 hospitalization was 225 among the lowest risk patient group compared with NNT of 4 among those with highest numbers of medical comorbidity. Conclusions. Monoclonal antibody treatment is associated with reduced hospitalization in vaccinated high-risk persons with mild to moderate COVID-19.

引用

页码：598 / 602

页数：5

共 14 条

[1] An EUA for Bamlanivimab-A Monoclonal Antibody for COVID-19 (Reprinted from Medical Letter on Drugs and Therapeutics, vol 62, pg 185-186, 2020)
不详
[J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2021, 325 (09): : 880 - 881
[2] Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine
Baden, Lindsey R.
El Sahly, Hana M.
Essink, Brandon
Kotloff, Karen
Frey, Sharon
Novak, Rick
Diemert, David
Spector, Stephen A.
Rouphael, Nadine
Creech, C. Buddy
McGettigan, John
Khetan, Shishir
Segall, Nathan
Solis, Joel
Brosz, Adam
Fierro, Carlos
Schwartz, Howard
Neuzil, Kathleen
Corey, Larry
Gilbert, Peter
Janes, Holly
Follmann, Dean
Marovich, Mary
Mascola, John
Polakowski, Laura
Ledgerwood, Julie
Graham, Barney S.
Bennett, Hamilton
Pajon, Rolando
Knightly, Conor
Leav, Brett
Deng, Weiping
Zhou, Honghong
Han, Shu
Ivarsson, Melanie
Miller, Jacqueline
Zaks, Tal
[J]. NEW ENGLAND JOURNAL OF MEDICINE, 2021, 384 (05) : 403 - 416
[3] Covid-19 Breakthrough Infections in Vaccinated Health Care Workers
Bergwerk, Moriah
Gonen, Tal
Lustig, Yaniv
Amit, Sharon
Lipsitch, Marc
Cohen, Carmit
Mandelboim, Michal
Gal Levin, Einav
Rubin, Carmit
Indenbaum, Victoria
Tal, Ilana
Zavitan, Malka
Zuckerman, Neta
Bar-Chaim, Adina
Kreiss, Yitshak
Regev-Yochay, Gili
[J]. NEW ENGLAND JOURNAL OF MEDICINE, 2021, 385 (16) : 1474 - 1484
[4] Effectiveness of Covid-19 Vaccines against the B.1.617.2 (Delta) Variant
Bernal, Jamie Lopez
Andrews, Nick
Gower, Charlotte
Gallagher, Eileen
Simmons, Ruth
Thelwall, Simon
Stowe, Julia
Tessier, Elise
Groves, Natalie
Dabrera, Gavin
Myers, Richard
Campbell, Colin N. J.
Amirthalingam, Gayatri
Edmunds, Matt
Zambon, Maria
Brown, Kevin E.
Hopkins, Susan
Chand, Meera
Ramsay, Mary
[J]. NEW ENGLAND JOURNAL OF MEDICINE, 2021, 385 (07) : 585 - 594
[5] Bierle DM, 2021, J PRIM CARE COMMUNIT, V12
[6] Centers for Disease Control and Prevention, 2021, COVID DATA TRACKER
[7] Ganesh R, 2021, J CLIN INVEST, V131
[8] Real-World Clinical Outcomes of Bamlanivimab and Casirivimab-Imdevimab Among High-Risk Patients With Mild to Moderate Coronavirus Disease 2019
Ganesh, Ravindra
Philpot, Lindsey M.
Bierle, Dennis M.
Anderson, Ryan J.
Arndt, Lori L.
Arndt, Richard F.
Culbertson, Tracy L.
Borgen, Molly J. Destro
Hanson, Sara N.
Kennedy, Brian D.
Kottke, Brian B.
Larsen, Jennifer J.
Ramar, Priya
Rosedahl, Jordan K.
Seville, Maria Teresa
Speicher, Leigh L.
Tulledge-Scheitel, Sidna M.
Wilker, Caroline G.
Razonable, Raymund R.
[J]. JOURNAL OF INFECTIOUS DISEASES, 2021, 224 (08) : 1278 - 1286
[9] Casirivimab-Imdevimab treatment is associated with reduced rates of hospitalization among high-risk patients with mild to moderate coronavirus disease-19
Razonable, Raymund R.
Pawlowski, Colin
O'Horo, John C.
Arndt, Lori L.
Arndt, Richard
Bierle, Dennis M.
Borgen, Molly Destro
Hanson, Sara N.
Hedin, Michelle C.
Lenehan, Patrick
Puranik, Arjun
Seville, Maria T.
Speicher, Leigh L.
Tulledge-Scheitel, Sidna M.
Venkatakrishnan, A. J.
Wilker, Caroline G.
Badley, Andrew D.
Ganesh, Ravindra
[J]. ECLINICALMEDICINE, 2021, 40
[10] A Framework for Outpatient Infusion of Antispike Monoclonal Antibodies to High-Risk Patients with Mild-to-Moderate Coronavirus Disease-19: The Mayo Clinic Model
Razonable, Raymund R.
Aloia, Nicole C. E.
Anderson, Ryan J.
Anil, Gokhan
Amdt, Lori L.
Amdt, Richard F.
Ausman, Sara E.
Bell, Sarah J.
Bierle, Dennis M.
Billings, Marcie L.
Bishop, Rachel K.
Cramer, Carl H.
Culbertson, Tracy L.
Dababneh, Ala S.
Derr, Amber N.
Epps, Kevin
Flaker, Susan M.
Ganesh, Ravindra
Gilmer, Mary A.
Urena, Eric Gomez
Gulden, Christopher R.
Haack, Tamara L.
Hanson, Sara N.
Herzog, Jenna R.
Heyliger, Alexander
Hokanson, Lex D.
Hopkins, Laura H.
Horecki, Richard J.
Krishna, Bipinchandra Hirisave
Huskins, W. Charles
Jackson, Tammy A.
Johnson, Ryan R.
Jorgenson, Betty
Kudma, Cory
Kennedy, Brian D.
Klingspom, Mary K.
Kottke, Brian
Larsen, Jennifer J.
Lessard, Sarah R.
Lutwick, Larry I.
Malone, Edward J., III
Matoush, Jennifer A.
Micallef, Ivana N.
Moehnke, Darcie E.
Mohamed, Muhanad
Ness, Colleena N.
Olson, Shelly M.
Orenstein, Robert
Palraj, Raj
Patel, Janki
[J]. MAYO CLINIC PROCEEDINGS, 2021, 96 (05) : 1250 - 1261

← 1 2 →